Stay updated on Safety Efficacy HMI-203 in MPS II Clinical Trial
Sign up to get notified when there's something new on the Safety Efficacy HMI-203 in MPS II Clinical Trial page.

Latest updates to the Safety Efficacy HMI-203 in MPS II Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed descriptions of a Phase 1 study for HMI-203 gene therapy for Mucopolysaccharidosis II, while a new revision number has been added.SummaryDifference21%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check88 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference1%
Stay in the know with updates to Safety Efficacy HMI-203 in MPS II Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety Efficacy HMI-203 in MPS II Clinical Trial page.